The potential of AI inspired approaches for patient monitoring in drug development for Huntington's disease: capturing the digital exhaust for activities of daily living.
- 1Neuroscience Development, Novartis AG, Basel, Switzerland.
- 2Clinical Innovation, Novartis Pharmaceuticals, Cambridge, MA, United States.
- 3Clinical and Translational Science Institute, Tufts University Medical Center, Boston, MA, United States.
Abstract
Diagnosis, assessment and monitoring of Huntington's disease (HD) requires measurement of a complex array of motor, cognitive and psychiatric symptoms over sustained periods. However, the prodromal stages often span over a decade with symptoms presenting in a non-linear manner with short term fluctuations. This presents challenges for investigational drug development as treatment effects may become masked. To help address this issue, a number of digital health technology tools are being investigated for use in HD studies with increasing degrees of utility and sophistication. Herein we outline how remote passive monitoring technologies could be integrated into managed care of HD patients, and have the potential to inform algorithms and digital tools which could be used to improve our understanding of disease trajectories and improve early detection rates. Steps to implementation and the potential to derive learnings from adjacent technologies is presented, affording a key opportunity for next- generation approaches to patient monitoring. Measures derived from such technologies will also provide data to capture disease progression and treatment effects with high fidelity and granularity, and complement existing clinical research outcomes (clinROs) and patient reported outcomes (PRO's). Given the ethical, economic, and societal burden presented by neurodegenerative diseases, such developments could have long term impact in managed healthcare.
Related
- CRISPR‐based therapeutic and modelling approaches in Huntington's disease: Progress, challenges and future directions
- Bioinformatics Analysis to Reveal Potential Targets of Huntington's Disease
- Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study
- Revisiting the Endophytic Fungi Residing Within Axonopus compressus: Molecular Identification, Antagonistic Potential, and Extracellular Enzyme Activities
- Exploring the therapeutic potential of Erycibe paniculata (Roxb.): metabolite profiling and antimalarial, anticancer, and modulation of NF-κB signaling pathway for anti-inflammatory activities
BibTeX
@article{khanna2026potential,
title = {{The potential of AI inspired approaches for patient monitoring in drug development for Huntington's disease: capturing the digital exhaust for activities of daily living.}},
author = {Amit Khanna and Graham Jones},
journal = {Frontiers in molecular medicine},
year = {2026},
month = oct,
doi = {10.3389/fmmed.2026.1966010},
url = {https://europepmc.org/article/MED/42898709},
note = {CC BY},
}
RIS
TY - JOUR
TI - The potential of AI inspired approaches for patient monitoring in drug development for Huntington's disease: capturing the digital exhaust for activities of daily living.
AU - Amit Khanna
AU - Graham Jones
PY - 2026
DA - 2026/10/05
JO - Frontiers in molecular medicine
DO - 10.3389/fmmed.2026.1966010
UR - https://europepmc.org/article/MED/42898709
AB - Diagnosis, assessment and monitoring of Huntington's disease (HD) requires measurement of a complex array of motor, cognitive and psychiatric symptoms over sustained periods. However, the prodromal stages often span over a decade with symptoms presenting in a non-linear manner with short term fluctuations. This presents challenges for investigational drug development as treatment effects may become masked. To help address this issue, a number of digital health technology tools are being investigated for use in HD studies with increasing degrees of utility and sophistication. Herein we outline how remote passive monitoring technologies could be integrated into managed care of HD patients, and have the potential to inform algorithms and digital tools which could be used to improve our understanding of disease trajectories and improve early detection rates. Steps to implementation and the potential to derive learnings from adjacent technologies is presented, affording a key opportunity for next- generation approaches to patient monitoring. Measures derived from such technologies will also provide data to capture disease progression and treatment effects with high fidelity and granularity, and complement existing clinical research outcomes (clinROs) and patient reported outcomes (PRO's). Given the ethical, economic, and societal burden presented by neurodegenerative diseases, such developments could have long term impact in managed healthcare.
SN - 2674-0095
ER -